Quantinno Capital Management LP Has $5.30 Million Stock Position in Qiagen N.V. $QGEN

Quantinno Capital Management LP cut its holdings in Qiagen N.V. (NYSE:QGEN) by 40.6% during the first quarter, Holdings Channel.com reports. The firm owned 132,392 shares of the company’s stock after selling 90,444 shares during the quarter. Quantinno Capital Management LP’s holdings in Qiagen were worth $5,301,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Massachusetts Financial Services Co. MA boosted its holdings in Qiagen by 1.1% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 24,205,881 shares of the company’s stock worth $1,088,538,000 after purchasing an additional 264,921 shares during the last quarter. Vanguard Group Inc. grew its position in Qiagen by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 9,542,944 shares of the company’s stock valued at $433,871,000 after purchasing an additional 118,135 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Qiagen by 12.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,429,424 shares of the company’s stock valued at $379,072,000 after buying an additional 906,589 shares during the last quarter. Deutsche Bank AG increased its stake in Qiagen by 9.7% in the 4th quarter. Deutsche Bank AG now owns 7,907,801 shares of the company’s stock valued at $355,614,000 after buying an additional 697,342 shares during the last quarter. Finally, Amundi lifted its position in Qiagen by 4.4% during the 3rd quarter. Amundi now owns 4,290,273 shares of the company’s stock worth $201,471,000 after buying an additional 181,509 shares in the last quarter. Institutional investors own 70.00% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on QGEN shares. Barclays set a $38.00 price objective on shares of Qiagen and gave the stock an “equal weight” rating in a research note on Wednesday, April 29th. Berenberg Bank set a $45.50 target price on Qiagen and gave the stock a “hold” rating in a report on Tuesday, July 14th. Kepler Capital Markets set a $38.60 price target on Qiagen and gave the company a “hold” rating in a research report on Thursday, June 25th. Zacks Research upgraded Qiagen from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 29th. Finally, Weiss Ratings lowered Qiagen from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, May 29th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $42.43.

Key Headlines Impacting Qiagen

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Qiagen reported second-quarter adjusted EPS of $0.62, above the $0.60 consensus estimate, while revenue of $535 million exceeded expectations of $527.5 million. Revenue was broadly unchanged year over year, but the company said its growth pillars delivered 5% growth at constant exchange rates and that sales exceeded its prior outlook for a decline. QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook
• Positive Sentiment: The company reaffirmed its full-year 2026 EPS outlook of approximately $2.43, in line with analyst expectations, while maintaining high profitability. Qiagen Earnings Conference Call
• Neutral Sentiment: Management’s second-quarter earnings call and presentation provided additional detail on the performance of Qiagen’s growth pillars and the company’s outlook, but did not materially change the full-year EPS forecast. Qiagen N.V. Q2 2026 Earnings Call Transcript
• Negative Sentiment: Third-quarter guidance was below consensus: EPS of $0.62 versus $0.63 expected and revenue of $538.3 million to $543.7 million versus $552.7 million expected. The revenue shortfall indicates analysts may need to reduce near-term estimates.
• Negative Sentiment: Although full-year EPS guidance matched consensus, full-year revenue guidance of roughly $2.1 billion was below the approximately $2.2 billion analyst estimate, tempering the impact of the quarterly beat.

Qiagen Stock Performance

Shares of QGEN stock opened at $41.71 on Friday. The company has a fifty day moving average price of $39.32 and a two-hundred day moving average price of $41.69. Qiagen N.V. has a one year low of $32.53 and a one year high of $57.81. The stock has a market cap of $8.59 billion, a P/E ratio of 21.37, a P/E/G ratio of 4.19 and a beta of 0.63. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.21 and a quick ratio of 2.57.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.02. The company had revenue of $535.00 million for the quarter, compared to analyst estimates of $527.50 million. Qiagen had a net margin of 19.49% and a return on equity of 14.24%. Qiagen’s revenue for the quarter was up .2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.60 EPS. Qiagen has set its FY 2026 guidance at 2.430- EPS. As a group, equities analysts predict that Qiagen N.V. will post 2.43 EPS for the current year.

Qiagen Increases Dividend

The firm also recently declared an annual dividend, which was paid on Tuesday, July 14th. Shareholders of record on Tuesday, July 7th were given a dividend of $0.35 per share. This represents a yield of 90.0%. This is a boost from Qiagen’s previous annual dividend of $0.26. The ex-dividend date of this dividend was Tuesday, July 7th. Qiagen’s dividend payout ratio (DPR) is presently 18.32%.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.